Cue Biopharma Inc (CUE)
NASDAQ:CUE
Want to see CUE full AI Analyst Report?
Top Page
Cue Biopharma
(NASDAQ:CUE)
Select Model
Select Model
Rating:52Neutral
Price Target:
$15.00
▲(4311.76% Upside)
Action:ReiteratedDate:05/02/26
The score is held back primarily by weak financial performance—ongoing losses and negative free cash flow despite revenue growth—implying continued reliance on external funding. Offsetting this, recent corporate events improve near-term liquidity and add pipeline/partner validation, while technicals are moderately constructive and valuation remains constrained by negative earnings.
Positive Factors
Proprietary Immuno-STAT platform
Cue’s Immuno-STAT platform is a durable scientific differentiator: selective T‑cell engagement creates a defensible mechanism of action that can be applied to multiple indications. That platform-level IP supports repeatable R&D programs and partner interest, enabling scalable pipeline expansion over time.
Negative Factors
Consistent negative operating and free cash flow
Sustained negative operating and free cash flow means Cue cannot self-fund development from operations and must rely on partnerships, milestone payments or new financings. That structural cash burn limits strategic flexibility, pressures prioritization of programs and raises the probability of future dilution absent product revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Immuno-STAT platform
Cue’s Immuno-STAT platform is a durable scientific differentiator: selective T‑cell engagement creates a defensible mechanism of action that can be applied to multiple indications. That platform-level IP supports repeatable R&D programs and partner interest, enabling scalable pipeline expansion over time.
Read all positive factors
Cue Biopharma (CUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$47.98M
Dividend YieldN/A
Average Volume (3M)238.59K
Price to Earnings (P/E)―
Beta (1Y)2.84
Revenue Growth195.75%
EPS Growth58.21%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.30
Shares Outstanding3,255,360
10 Day Avg. Volume365,762
30 Day Avg. Volume238,588
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.09
Price to Sales (P/S)1.05
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue0.41
Enterprise Value/Gross Profit0.46
Enterprise Value/Ebitda-0.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-14.1
Revenue Forecast (FY)$1.00M
Cue Biopharma Business Overview & Revenue Model
Company Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug cand...
How the Company Makes Money
Cue Biopharma primarily makes money from (1) collaboration and license-related revenue and (2) occasional financing-related and other operating income, rather than from product sales, because it is clinical-stage and does not have marketed therape...
Cue Biopharma Earnings Call Summary
Earnings Call Date:Aug 19, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The call presented several positive developments in clinical trials and strategic financial management, but also noted delays in trial launches and competitive market challenges.Positive Updates
CUE-101 and Pembrolizumab Combination Shows Promising Results
CUE-101 in combination with Pembrolizumab shows an objective response rate (ORR) of 46% in patients with CPS ≥ 1, compared to the historical ORR of 19% with Pembrolizumab alone. The 12-month overall survival (OS) is 90% with a median OS of 21.8 months.
Negative Updates
Delays in Capital-Intensive Trials
Measures to delay the launch of capital-intensive trials were implemented, affecting the pace of certain developments.
Read all updates
Q2-2024 Updates
Positive
Negative
CUE-101 and Pembrolizumab Combination Shows Promising Results
CUE-101 in combination with Pembrolizumab shows an objective response rate (ORR) of 46% in patients with CPS ≥ 1, compared to the historical ORR of 19% with Pembrolizumab alone. The 12-month overall survival (OS) is 90% with a median OS of 21.8 months.
Read all positive updates
Company Guidance
During Cue Biopharma's Q2 2024 earnings call, the executives provided guidance on several metrics and strategic priorities. They highlighted their focus on reducing capital requirements by achieving a cash burn reduction from $40 million to $30 million annually, extending their runway to mid-2025. The company is advancing its CUE-101 and CUE-102 oncology programs, with CUE-101 showing an objective response rate of 46% and a notable 12-month overall survival rate of 90% in a combination trial with pembrolizumab. Cue-401, in collaboration with ONO Pharmaceuticals, targets autoimmune diseases, with lead candidate selection anticipated in Q1 2025. Additionally, CUE-501 is being positioned for strategic partnering, aimed at addressing B-cell-mediated autoimmune diseases. The company's approach includes leveraging strategic partnerships to optimize resource allocation and bolster cash flow through milestone payments and potential co-development agreements.Cue Biopharma Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
54
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 27.47M | 9.29M | 5.49M | 1.25M | 14.94M |
| Gross Profit | 23.99M | 9.29M | -32.61M | 1.25M | 16.72M |
| EBITDA | -23.04M | -37.53M | -46.05M | -50.49M | -45.44M |
| Net Income | -26.60M | -40.67M | -50.73M | -53.01M | -44.16M |
Balance Sheet | |||||
| Total Assets | 42.21M | 32.19M | 61.53M | 91.28M | 83.40M |
| Cash, Cash Equivalents and Short-Term Investments | 27.14M | 23.39M | 48.51M | 76.29M | 64.37M |
| Total Debt | 4.20M | 8.88M | 14.70M | 19.32M | 12.02M |
| Total Liabilities | 15.78M | 14.69M | 24.45M | 25.60M | 17.91M |
| Stockholders Equity | 26.43M | 17.50M | 37.09M | 65.68M | 65.49M |
Cash Flow | |||||
| Free Cash Flow | -21.86M | -36.40M | -39.96M | -41.98M | -39.75M |
| Operating Cash Flow | -21.69M | -36.33M | -39.96M | -41.81M | -38.84M |
| Investing Cash Flow | 75.00K | 32.00K | 25.00M | -24.61M | 9.11M |
| Financing Cash Flow | 26.29M | 10.24M | 11.86M | 53.66M | 19.23M |
Cue Biopharma Technical Analysis
Positive
0.34
Price Trends
0.31
Positive
0.36
Positive
0.56
Positive
Market Momentum
0.08
Negative
68.88
Neutral
77.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Positive. The current price of 0.34 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.31, and below the 200-day MA of 0.56, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 68.88 is Neutral, neither overbought nor oversold. The STOCH value of 77.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CUE.
Cue Biopharma Risk Analysis
Cue Biopharma disclosed 64 risk factors in its most recent earnings report. Cue Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cue Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $71.68M | -1.19 | -57.23% | ― | ― | 16.95% | |
52 Neutral | $47.98M | -1.09 | -165.19% | ― | 195.75% | 58.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $37.06M | -1.22 | -28.16% | ― | -44.59% | 93.48% | |
42 Neutral | $26.94M | -0.31 | 763.31% | ― | -15.81% | -113.06% | |
| ― | $80.69M | -2.19 | -3.76% | ― | ― | 36.74% |
* Healthcare Sector Average
CUE
Cue Biopharma
30.42
7.84
34.73%
CELU
Celularity
0.96
-0.64
-40.19%
ALGS
Aligos Therapeutics
6.09
0.49
8.75%
GNTA
Genenta Science SpA Sponsored ADR
0.73
-3.29
-81.84%
MAIA
MAIA Biotechnology, Inc.
1.34
-0.71
-34.63%
ACRV
Acrivon Therapeutics, Inc.
2.09
0.68
48.23%
Cue Biopharma Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Cue Biopharma licenses Ascendant-221 and raises new capital
Positive
May 1, 2026
On April 30, 2026, Cue Biopharma entered a global (ex‑Greater China) exclusive license with Ascendant Health Sciences for Ascendant‑221, a Phase 2 dual‑mechanism anti‑IgE antibody, paying $15 million upfront and committing ...
Regulatory Filings and ComplianceStock Split
Cue Biopharma Announces 1-for-30 Reverse Stock Split
Neutral
Apr 22, 2026
Cue Biopharma, Inc., a Nasdaq-listed immunotherapy-focused biotechnology company, moved to adjust its capital structure while maintaining its existing authorized share count and par value, reflecting efforts to preserve financial and listing flexi...
Executive/Board ChangesShareholder MeetingsStock Split
Cue Biopharma Shareholders Approve Reverse Stock Split Flexibility
Neutral
Apr 13, 2026
At its April 13, 2026 annual meeting, Cue Biopharma stockholders elected six directors, including Pasha Sarraf and Pamela Garzone, to serve until the next annual meeting, while noting that all votes cast for former CEO Usman Azam, who resigned on ...
Business Operations and StrategyFinancial Disclosures
Cue Biopharma Reaches Key Preclinical Milestone With Boehringer
Positive
Apr 7, 2026
On April 1, 2026, Cue Biopharma, Inc. reported that Boehringer Ingelheim selected its first compound for lead optimization under their April 10, 2025 collaboration to develop differentiated B cell depletion molecules, including Cue Biopharma’...
Executive/Board ChangesShareholder Meetings
Cue Biopharma Names Lucinda Warren Interim Chief Executive
Neutral
Mar 27, 2026
On March 26, 2026, Cue Biopharma’s board appointed Chief Financial and Business Officer Lucinda Warren as interim president and chief executive officer, effective March 27, 2026, following the resignation of CEO and director Usman Azam, who ...
Regulatory Filings and ComplianceShareholder Meetings
Cue Biopharma Sets 2026 Annual Meeting, Proposal Deadlines
Neutral
Feb 18, 2026
Cue Biopharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 13, 2026, and set February 28, 2026 as the key deadline for shareholders seeking to submit proposals for inclusion in the company’s proxy materials under SEC...
Business Operations and StrategyExecutive/Board Changes
Cue Biopharma Names Lucinda Warren Chief Financial Officer
Neutral
Feb 12, 2026
On February 9, 2026, Cue Biopharma’s board appointed Chief Business Officer Lucinda Warren as Chief Financial and Business Officer, consolidating oversight of the company’s finance and business functions under a single executive. Warre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.